奥沙利铂联合卡培他滨辅助化疗方案对Ⅲ期胃癌术后患者的疗效分析  

Effectiveness of oxaliplatin combined with capecitabine adjuvant chemotherapy on stage Ⅲ gastric cancer

作　　者：王冠青 韩雅琳[1] 陈丽[1] 戴广海[1] WANG Guanqing;HAN Yalin;CHEN Li;DAI Guanghai(Department of Medical Oncology,the First Medical Center,Chinese PLA General Hospital,Beijing 100853,China)

机构地区：[1]解放军总医院第一医学中心肿瘤内科,北京100853

出　　处：《解放军医学院学报》2019年第3期227-230,共4页Academic Journal of Chinese PLA Medical School

摘　　要：目的观察Ⅲ期胃癌患者术后应用奥沙利铂联合卡培他滨(XELOX)方案的临床疗效。方法回顾性分析2009年1月-2014年12月于本中心接受胃癌根治术且病理证实为Ⅲ期胃癌的患者132例,观察组83例采用XELOX方案,对照组49例采用SOX方案。比较两组的生存率及不良反应。结果两组患者性别、年龄、肿瘤位置、病理分型、分化程度、肿瘤大小、浸润深度、TNM分期等差异均无统计学意义。研究组与对照组中位无病生存时间分别为23.6个月、16.7个月,无统计学差异(P=0.129),但生存曲线分离趋势较明显。观察组与对照组中位总生存时间分别为37.5个月、36.0个月,亦无统计学差异(P=0.500)。对照组中性粒细胞减少(62.2%vs 30.6%)及乏力(84.2%vs 52.1%)发生率明显高于观察组(P均<0.05),其他不良反应包括肝功能损伤、肾功能损伤、恶心呕吐等均无统计学差异(P> 0.05)。结论 XELOX方案对Ⅲ期胃癌患者疗效确切,且不良反应小,可作为临床首选方案。Objective To observe the clinical effectiveness of oxaliplatin combined with capecitabine(XELOX)in patients with stageⅢgastric cancer.Methods Clinical data about patients with stageⅢgastric cancer who underwent radical gastrectomy and postoperative chemotherapy in our center from January 2009 to December 2014 were retrospectively analyzed.There were83 patients in the observation group who received XELOX regimen,and 49 cases in the control group with SOX regimen.The survival rate and adverse reactions of the two groups were compared.Results There was no signicant difference in gender,age,tumor location,pathological type,degree of differentiation,tumor size,depth of invasion,and TNM stage between the two groups.The median disease-free survival time(mDFS)of the observation group and the control group was 23.6 months versus 16.7 months(P=0.129);The median overall survival time(mOS)was 37.5 versus 36.0 months(P=0.500).The incidences of neutropenia(62.2%vs30.6%)and fatigue(84.2%vs 52.1%)in the control group were signicantly higher than those in the observation group(P<0.05,respectively).Other adverse reactions including liver function damage,renal function damage,nausea and vomiting had no signicant difference.Conclusion The XELOX regimen is effective on stageⅢgastric cancer,and the adverse reactions are tolerable,which can be used as the rst choice.

关 键 词：进展期胃癌 胃癌根治术 辅助化疗 生存率 

分 类 号：R735.2[医药卫生—肿瘤]